Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KLK6 drug discovery. The following table summarizes the key reagents and related targets for building robust assays for KLK6 drug development.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Active WT) | KLK6 Recombinant Protease (Active & Zymogen). HEK293 Expressed, Native Glycosylation, >95% Purity, Endotoxin <1 EU/µg. Sequence Verified. | View KLK6 Products |
| Antigen (Mutant) | KLK6 Catalytic Dead Mutant (S197A). Rational design for binding assays without proteolytic turnover. Theoretical MW confirmed. | View KLK6 Products |
| Benchmark Ab | Anti-KLK6 Neutralizing Antibody. Recombinant mAb with epitope mapped to catalytic cleft region. Positive control for neutralization assays. | View KLK6 Products |
| Gene Delivery | KLK6 Promise-ORF / Lentivirus. Full-length ORF for stable secretory cell lines. | View KLK6 Products |
| Validator | KLK6 siRNA Set (3 unique sequences). For knockdown verification and specificity checks. | View KLK6 Products |
| Related Target: KLK5 | KLK family paralog for selectivity counter-screening. | View KLK5 Products |
| Related Target: KLK7 | Structural homolog for selectivity counter-screening (skin barrier, cancer). | View KLK7 Products |
| Related Target: KLK3 (PSA) | Closely related family member for selectivity profiling, especially in prostate. | View KLK3 Products |
| Related Target: KLK4 | Co-expressed in CNS and prostate; counter-screening essential. | View KLK4 Products |
| Related Target: F2R (PAR1) | Downstream signaling receptor activated by KLK6 proteolytic activity. | View F2R Products |
| Related Target: SNCA | Alpha-synuclein, a downstream cleavage substrate in CNS (Parkinson's). | View SNCA Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (KLK family homology >40% identity) | Homolog panel proteins (KLK5, KLK6, KLK7, KLK3, KLK4) strictly verified by mass spec; Sequence Verified >95% purity. |
| Distinguishing Active Protease vs Zymogen | Available as Active (mature) and Pro-form (zymogen); Endotoxin Controlled for sensitive cell assays. |
| Lack of Neutralization Controls | Anti-KLK6 Benchmark Antibodies included for assay standardization. |
| False Positives in Activity Assays | Catalytic-dead Mutant Protein included as negative control for binding specificity. Validated siRNA for on-target confirmation. |
| Catalytic Activity vs. Binding Disruption (active site vs exosite) | Active WT + S197A Mutant Pair: Direct comparison of catalytic vs. non-catalytic binding modes. |
| Endogenous Inhibitor Contamination | Endotoxin <1 EU/µg; Host cell protein <100 ppm by ELISA. |
Live KLK6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLK6 therapeutics is intensifying, with academic and biotech players advancing from biomarker discovery to targeted intervention. KLK6 is a secreted serine protease (Peptidase S1 family, UniProt Q92876) implicated in demyelination (Multiple Sclerosis), amyloid processing (Alzheimer's Disease), and tumor microenvironments (ovarian, pancreatic, colon). Known mutations such as rs61469141 (dbSNP) may affect activity or conformation and serve as tools for drug resistance studies. Current pipelines are dominated by monoclonal antibodies targeting exosites and small molecule inhibitors aimed at the catalytic triad. The next wave of R&D is shifting toward highly selective biologics and brain-penetrant modalities for CNS indications, requiring rigorous counter-screening against the 15-member kallikrein family. BBB shuttle technologies (e.g., Fc-engineered antibodies) are emerging as key differentiators for antibody approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Academic consortia, Roche (early), Emerging biotech | Multiple Sclerosis, Alzheimer's Disease, Parkinson's | Neutralization Assay (Need active & zymogen KLK6); Exosite vs active site mapping (WT + Mutant) |
| Small Molecule Inhibitor | Evotec, Structure-based biotechs | Alzheimer's Disease, Solid Tumors (ovarian, colon) | Enzymatic Activity Assay (Need high-purity active protein, family selectivity panel) |
| ADC / Targeted Biologic | Oncology-focused biotech | Ovarian Cancer, Pancreatic Cancer | Internalization & Binding (Need high-purity antigen; PAR1 pathway validation) |
| Gene Therapy / siRNA | Academic / Biotech spin-offs | Aggressive Tumors, Neuroinflammation | Knockdown Validation (Need sequence-verified siRNA) |
| Antibody-Enzyme Fusion | Emerging biotech platforms | Neuroinflammation | Selectivity Panel (Need KLK3, KLK4, KLK10 family proteins) |
| Biomarker / Companion Dx | Diagnostic majors | CSF Monitoring | Calibrated Reference Standards (Sequence Verified, Accurate Concentration) |